Post-earnings recap
Reported
Tue, May 12, 2015
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Despite missing EPS expectations significantly, Xenon Pharmaceutical's stock rose by 7.79% in reaction to the earnings report. Investors may have responded positively to management's focus on clinical programs, indicating potential future growth. The lack of revenue data and guidance suggests uncertainty about the company's short-term performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.30 | N/A | -2900.00% |
| Revenue | N/A | N/A | N/A |
Management acknowledged the challenges in meeting EPS expectations. They emphasized their commitment to ongoing clinical development.
Management did not provide specific revenue guidance for the upcoming quarters.
The company is focused on advancing its clinical programs.